Cantor Fitzgerald Cuts Amneal Pharmaceuticals (NYSE:AMRX) Price Target to $14.00

Amneal Pharmaceuticals (NYSE:AMRX) had its price target reduced by analysts at Cantor Fitzgerald from $35.00 to $14.00 in a note issued to investors on Wednesday, The Fly reports. The firm presently has an “overweight” rating on the stock. Cantor Fitzgerald’s target price points to a potential upside of 91.26% from the company’s current price.

Other equities research analysts have also recently issued research reports about the stock. SunTrust Banks started coverage on shares of Amneal Pharmaceuticals in a research report on Tuesday, March 19th. They issued a “buy” rating and a $16.00 target price for the company. ValuEngine cut shares of Amneal Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, April 5th. Zacks Investment Research raised shares of Amneal Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Wednesday, May 8th. Svb Leerink cut shares of Amneal Pharmaceuticals from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $16.00 to $12.00 in a research report on Friday, March 8th. Finally, Barclays started coverage on shares of Amneal Pharmaceuticals in a research report on Tuesday. They issued an “equal weight” rating and a $9.00 target price for the company. One analyst has rated the stock with a sell rating, seven have issued a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $16.73.

AMRX stock opened at $7.32 on Wednesday. The company has a debt-to-equity ratio of 3.44, a current ratio of 2.11 and a quick ratio of 1.37. Amneal Pharmaceuticals has a one year low of $7.19 and a one year high of $24.48. The firm has a market cap of $2.19 billion, a price-to-earnings ratio of 7.71, a P/E/G ratio of 0.45 and a beta of 1.63.



Amneal Pharmaceuticals (NYSE:AMRX) last released its quarterly earnings data on Thursday, May 9th. The company reported $0.11 EPS for the quarter, missing the Zacks’ consensus estimate of $0.18 by ($0.07). Amneal Pharmaceuticals had a positive return on equity of 32.14% and a negative net margin of 3.75%. The company had revenue of $446.00 million for the quarter, compared to the consensus estimate of $438.18 million. The firm’s revenue for the quarter was up 4.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Amneal Pharmaceuticals will post 0.91 earnings per share for the current fiscal year.

In other news, SVP Pradeep Bhadauria acquired 7,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 15th. The stock was acquired at an average price of $8.48 per share, with a total value of $59,360.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Andrew S. Boyer acquired 19,000 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The shares were purchased at an average cost of $9.46 per share, with a total value of $179,740.00. The disclosure for this purchase can be found here. Insiders have purchased 41,000 shares of company stock valued at $387,300 in the last ninety days. 26.34% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Marshall Wace North America L.P. raised its stake in Amneal Pharmaceuticals by 87.6% during the first quarter. Marshall Wace North America L.P. now owns 66,512 shares of the company’s stock worth $942,000 after acquiring an additional 31,063 shares in the last quarter. Marshall Wace LLP raised its stake in Amneal Pharmaceuticals by 487.8% during the first quarter. Marshall Wace LLP now owns 492,275 shares of the company’s stock worth $6,977,000 after acquiring an additional 408,533 shares in the last quarter. Hsbc Holdings PLC raised its stake in Amneal Pharmaceuticals by 20.9% during the first quarter. Hsbc Holdings PLC now owns 31,356 shares of the company’s stock worth $445,000 after acquiring an additional 5,419 shares in the last quarter. Cresset Asset Management LLC acquired a new position in Amneal Pharmaceuticals during the first quarter worth about $29,000. Finally, Geode Capital Management LLC increased its stake in shares of Amneal Pharmaceuticals by 7.1% in the first quarter. Geode Capital Management LLC now owns 953,580 shares of the company’s stock valued at $13,512,000 after buying an additional 63,600 shares during the period. 36.05% of the stock is owned by institutional investors and hedge funds.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

Further Reading: What are the benefits of a balanced fund?

The Fly

Analyst Recommendations for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.